Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $63

Benzinga · 01/06/2023 13:00
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and lowers the price target from $66 to $63.